COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report

Autoimmune hemolytic anemia (AIHA) is a very rare presentation of COVID-19, and AIHA due to COVID-19 alone (i.e., in the absence of an associated underlying disorder) is extremely rare. Warm agglutinin disease accounts for the majority of AIHA in general. Here, we report a case of a 23-year-old male...

Full description

Bibliographic Details
Main Authors: Lakshmi J Nair, Aravind Regukumar, K T Baalamurugan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Saudi Journal of Medicine and Medical Sciences
Subjects:
Online Access:http://www.sjmms.net/article.asp?issn=1658-631X;year=2021;volume=9;issue=3;spage=276;epage=279;aulast=Nair
id doaj-c9ddc0ddad924c189458fabb585cc0a5
record_format Article
spelling doaj-c9ddc0ddad924c189458fabb585cc0a52021-10-07T05:55:09ZengWolters Kluwer Medknow PublicationsSaudi Journal of Medicine and Medical Sciences1658-631X2021-01-019327627910.4103/sjmms.sjmms_203_21COVID-19-Associated severe autoimmune hemolytic anemia: A rare case reportLakshmi J NairAravind RegukumarK T BaalamuruganAutoimmune hemolytic anemia (AIHA) is a very rare presentation of COVID-19, and AIHA due to COVID-19 alone (i.e., in the absence of an associated underlying disorder) is extremely rare. Warm agglutinin disease accounts for the majority of AIHA in general. Here, we report a case of a 23-year-old male with bronchial asthma who was referred to our hospital with SARS-COV-2 infection and severe anemia presenting as acute immune-mediated hemolytic crisis due to warm autoimmune hemolytic anemia (AIHA). Extensive laboratory testing was performed, including polyspecific direct antiglobulin test, complete autoimmune workup and common infections leading to AIHA were ruled out by serology and molecular methods. The patient required multiple blood transfusions and other therapeutic interventions before clinical stabilization. Treatment of new-onset AIHA is always challenging in the presence of an active viral replication; combining immunosuppression with active COVID-19 infection creates extremely difficult diagnostic and management settings, as this case illustrates.http://www.sjmms.net/article.asp?issn=1658-631X;year=2021;volume=9;issue=3;spage=276;epage=279;aulast=Nairautoimmune hemolytic anemiacovid-19hemolysissars-cov-2warm antibody
collection DOAJ
language English
format Article
sources DOAJ
author Lakshmi J Nair
Aravind Regukumar
K T Baalamurugan
spellingShingle Lakshmi J Nair
Aravind Regukumar
K T Baalamurugan
COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report
Saudi Journal of Medicine and Medical Sciences
autoimmune hemolytic anemia
covid-19
hemolysis
sars-cov-2
warm antibody
author_facet Lakshmi J Nair
Aravind Regukumar
K T Baalamurugan
author_sort Lakshmi J Nair
title COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report
title_short COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report
title_full COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report
title_fullStr COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report
title_full_unstemmed COVID-19-Associated severe autoimmune hemolytic anemia: A rare case report
title_sort covid-19-associated severe autoimmune hemolytic anemia: a rare case report
publisher Wolters Kluwer Medknow Publications
series Saudi Journal of Medicine and Medical Sciences
issn 1658-631X
publishDate 2021-01-01
description Autoimmune hemolytic anemia (AIHA) is a very rare presentation of COVID-19, and AIHA due to COVID-19 alone (i.e., in the absence of an associated underlying disorder) is extremely rare. Warm agglutinin disease accounts for the majority of AIHA in general. Here, we report a case of a 23-year-old male with bronchial asthma who was referred to our hospital with SARS-COV-2 infection and severe anemia presenting as acute immune-mediated hemolytic crisis due to warm autoimmune hemolytic anemia (AIHA). Extensive laboratory testing was performed, including polyspecific direct antiglobulin test, complete autoimmune workup and common infections leading to AIHA were ruled out by serology and molecular methods. The patient required multiple blood transfusions and other therapeutic interventions before clinical stabilization. Treatment of new-onset AIHA is always challenging in the presence of an active viral replication; combining immunosuppression with active COVID-19 infection creates extremely difficult diagnostic and management settings, as this case illustrates.
topic autoimmune hemolytic anemia
covid-19
hemolysis
sars-cov-2
warm antibody
url http://www.sjmms.net/article.asp?issn=1658-631X;year=2021;volume=9;issue=3;spage=276;epage=279;aulast=Nair
work_keys_str_mv AT lakshmijnair covid19associatedsevereautoimmunehemolyticanemiaararecasereport
AT aravindregukumar covid19associatedsevereautoimmunehemolyticanemiaararecasereport
AT ktbaalamurugan covid19associatedsevereautoimmunehemolyticanemiaararecasereport
_version_ 1716839603227328512